Globus Medical reported solid preliminary Q4 results, says Piper Jaffray After Globus reported higher than expected preliminary Q4 revenue, Piper Jaffray continues to view the spine market as stable, if not modestly improving. The firm continues to recommend buying the stock.
News For GMED From The Last 14 Days
Check below for free stories on GMED the last two weeks.
Globus Medical downgraded to Hold from Buy at WallachBeth WallachBeth downgraded Globus Medical citing valuation but raised its price target for shares to $27 from $23 following the company's Q4 results.